Who makes XAF5, concentration A?

XAF5, concentration A is developed by Topokine Therapeutics, Inc..

What development phase is XAF5, concentration A in?

XAF5, concentration A is in Phase 1.

Last reviewed 2026-05-14 · How we verify

XAF5, concentration A

Topokine Therapeutics, Inc. · Phase 1 active Small molecule

At a glance

Generic name	XAF5, concentration A
Sponsor	Topokine Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 2b/3 Study of XAF5 Ointment for Steatoblepharon (Undereye Bags) (PHASE2, PHASE3)
Phase 1 Study of XAF5 Gel Applied to Skin of Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

XAF5, concentration A CI brief — competitive landscape report
XAF5, concentration A updates RSS · CI watch RSS
Topokine Therapeutics, Inc. portfolio CI